O
Oronzo Brunetti
Researcher at University of Bari
Publications - 123
Citations - 2542
Oronzo Brunetti is an academic researcher from University of Bari. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 23, co-authored 104 publications receiving 1608 citations.
Papers
More filters
Journal ArticleDOI
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells
Valeria Simone,Sabino Ciavarella,Oronzo Brunetti,Annalisa Savonarola,Mauro Cives,Marco Tucci,Giuseppina Opinto,Eugenio Maiorano,Francesco Silvestris +8 more
TL;DR: Everolimus significantly inhibited the differentiation of OCs and their in vitro bone-resorbing activity, and also found decreases of both mRNA and secreted pro-OC factors such as M-CSF, IL-6, and IL-1β, whose lower ELISA levels paralleled the defective phosphorylation of NFkB pathway effectors.
Journal ArticleDOI
Immunotherapy for colorectal cancer: where are we heading?
Debora Basile,Silvio Garattini,Marta Bonotto,Elena Ongaro,Mariaelena Casagrande,Monica Cattaneo,Valentina Fanotto,Elisa De Carlo,Fotios Loupakis,Federica Urbano,Francesca Negri,Nicoletta Pella,Marco Russano,Oronzo Brunetti,Mario Scartozzi,Daniele Santini,Nicola Silvestris,Andrea Casadei Gardini,Marco Puzzoni,Lorenzo Calvetti,Nadia Cardarelli,Giuseppe Aprile +21 more
TL;DR: The authors discuss the delicate balance between immune-stimulating and immune-suppressive networks that occur in the tumor microenvironment and potential prognostic and predictive immune biomarkers based on immune and molecular classifications that have been proposed.
Journal ArticleDOI
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Andrea Casadei Gardini,Luca Faloppi,Serena De Matteis,Francesco Giuseppe Foschi,Nicola Silvestris,Francesco Tovoli,Vincenzo Palmieri,Giorgia Marisi,Oronzo Brunetti,Umberto Vespasiani-Gentilucci,Giuseppe Perrone,Martina Valgiusti,Anna Maria Granato,Giorgio Ercolani,Giulia Negrini,Emiliano Tamburini,Giuseppe Aprile,Alessandro Passardi,Daniele Santini,Stefano Cascinu,Giovanni Luca Frassineti,Mario Scartozzi +21 more
TL;DR: The use of sorafenib was associated with poor progression-free survival (PFS) and overall survival (OS) and the role of sirtuin-3 (SIRT-3), a protein involved in metabolic diseases and acknowledged as a tumour suppressor in HCC, in this resistance, was clarified.
Journal ArticleDOI
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer.
Letizia Porcelli,Rosa Maria Iacobazzi,Roberta Di Fonte,Simona Serratì,Angelica Intini,Antonio Giovanni Solimando,Oronzo Brunetti,Angela Calabrese,Francesco Leonetti,Amalia Azzariti,Nicola Silvestris +10 more
TL;DR: In conclusion, MC play a pivotal role in the resistance to GEM/NAB, a correlation between high level of circulating pro-inflammatory/ immunosuppressive cytokines and unresponsiveness was found in PDAC patients.
Journal ArticleDOI
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue
Vito Longo,Oronzo Brunetti,Antonio Gnoni,Stefano Cascinu,Giampietro Gasparini,Vito Lorusso,Domenico Ribatti,Nicola Silvestris +7 more
TL;DR: PDAC is characterized by excessive dense extracellular matrix deposition associated to vasculature collapse and hypoxia with low drug delivery, explaining at least partly the low efficacy of antiangiogenic drugs in this cancer.